A study of paclitaxel induced maculopathy at the tertiary care centre of North West Rajasthan
Keywords:
Cystoid Macular oedema, PTX, ChemotherapyAbstract
Background: Paclitaxel (PTX) is important cytotoxic anti-cancer agents, are widely used to treat various solid tumours. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported.
Aims and objectives: 1) To study the demography of patients presenting with paclitaxel induced maculopathy at tertiary centre, 2) Various presentation and clinical manifestation of patients. 3) Establish a specific cause-effect relationship between paclitaxel and ocular complications.
Methodology: This prospective observational study was conducted on 50 patients who are aged between 30-60 year and who were prescribed Paclitaxel chemotherapy for the various carcinoma and reported to the OPD of Eye Department of Sardar Patel Medical College and associated group of hospitals, Bikaner. Eye screening was done before and After chemotherapy. Visual acuity was checked and OCT was done to check any macular oedema.
Result: Maximum (24%) study population belongs to 51-55 years age group and mean age of study population was 49.34 ± 8.56 years. 64% were females. 58% belongs to rural area. 22 Patients (44%) of study population had carcinoma since past 3-6 Years. Maximum study population had Breast carcinoma (54%), followed by Lung carcinoma (12%). Before paclitaxel treatment visual acuity was 6/6-6/9 in 48 eyes while 6/9-6/12 and 6/12-6/18 in 32 and 20 eyes respectively. After paclitaxel therapy visual acuity was decreased in 2 Eyes.
Conclusion: CME is a complication of paclitaxel. Physician should be aware of visual complaints when prescribing paclitaxel. Prompt diagnosis and discontinuation of the drug help visual recovery.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2021 International Journal of Biomedical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.